文献速递腹部胸部CT

胃食管结合部腺癌治疗反应评估:治疗前与治疗后碘密度成像的作用

Evaluating Treatment Response in GEJ Adenocarcinoma: The Role of Pretherapeutic and Posttherapeutic Iodine Mapping.
PubMed 文献 · Invest Radiol · 2024-01-24

这项回顾性队列研究纳入62例胃食管结合部腺癌患者,在诊断时和术前分别行多期相光谱CT扫描生成碘密度图,评估治疗前及治疗后碘密度预测新辅助化疗组织病理学反应的价值。归一化Δ碘密度与肿瘤消退分级显著相关,鉴别反应者与无反应者的AUC达0.95,敏感度和特异度分别为92.3%和92.1%;治疗后碘密度AUC为0.88,诊断时碘密度和RECIST不能区分反应者与无反应者。

要点

  • 归一化Δ碘密度(诊断时减新辅助治疗后)鉴别反应者与无反应者的AUC为0.95。
  • 新辅助治疗后碘密度AUC为0.88, cutoff为0.266。
  • 诊断时碘密度和RECIST不能区分反应者与无反应者。

核心结论

  • 胃食管结合部腺癌新辅助治疗后碘密度的变化可能作为治疗反应的潜在替代指标。

研究设计与样本

  • 回顾性队列研究,共纳入62例胃食管结合部腺癌患者,诊断时和术前均行多期相CT扫描,基于光谱CT数据生成碘密度图,以Becker等(Cancer. 2003;98:1521-1530)的肿瘤消退分级作为组织病理学参考标准,两名有经验的放射科医生盲法在肿瘤最高密度区域放置5个定义ROI并取最大值分析,碘密度归一化至主动脉碘摄取,同时按标准RECIST评估肿瘤反应。

诊断标准与关键数值

  • 归一化Δ碘密度(诊断时碘密度减新辅助治疗后碘密度)鉴别反应者与无反应者的AUC为0.95,敏感度92.3%,特异度92.1%。
  • 新辅助治疗后碘密度鉴别反应者与无反应者的AUC为0.88,敏感度86.8%,特异度84.6%,cutoff为0.266。
  • 诊断时碘密度和RECIST不能提供区分反应者与无反应者的信息。
  • 使用新辅助治疗后碘密度的cutoff值,在11例患者的测试集中两名阅片者均实现了反应者与无反应者的可靠分类。
  • 组内相关系数显示阅片者间信度极佳(组内相关系数>0.9)。

临床应用与阅片要点

  • 以归一化Δ碘密度的cutoff值作为治疗反应定义时,反应者生存期显著更长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Neoadjuvant therapy regimens have significantly improved the prognosis of GEJ (gastroesophageal junction) cancer; however, there are a significant percentage of patients who benefit from earlier resection or adapted therapy regimens, and the true response rate can only be determined histopathologically. Methods that allow preoperative assessment of response are lacking.

PURPOSE: The purpose of this retrospective study is to assess the potential of pretherapeutic and posttherapeutic spectral CT iodine density (IoD) in predicting histopathological response to neoadjuvant chemotherapy in patients diagnosed with adenocarcinoma of the GEJ.

METHODS: In this retrospective cohort study, a total of 62 patients with GEJ carcinoma were studied. Patients received a multiphasic CT scan at diagnosis and preoperatively. Iodine-density maps were generated based on spectral CT data. All tumors were histopathologically analyzed, and the tumor regression grade (TRG) according to Becker et al ( Cancer . 2003;98:1521-1530) was determined. Two experienced radiologists blindly placed 5 defined ROIs in the tumor region of highest density, and the maximum value was used for further analysis. Iodine density was normalized to the aortic iodine uptake. In addition, tumor response was assessed according to standard RECIST measurement. After assessing interrater reliability, the correlation of IoD values with treatment response and with histopathologic TRG was evaluated.

RESULTS: The normalized ΔIoD (IoD at diagnosis - IoD after neoadjuvant treatment) and the normalized IoD after neoadjuvant treatment correlated significantly with the TRG. For the detection of responders and nonresponders, the receiver operating characteristic (ROC) curve for normalized ΔIoD yielded the highest area under the curve of 0.95 and achieved a sensitivity and specificity of 92.3% and 92.1%, respectively. Iodine density after neoadjuvant treatment achieved an area under the curve of 0.88 and a sensitivity and specificity of 86.8% and 84.6%, respectively (cutoff, 0.266). Iodine density at diagnosis and RECIST did not provide information to distinguish responders from nonresponders. Using the cutoff value for IoD after neoadjuvant treatment, a reliable classification of responders and nonresponders was achieved for both readers in a test set of 11 patients. Intraclass correlation coefficient revealed excellent interrater reliability (intraclass correlation coefficient, >0.9). Lastly, using the cutoff value for normalized ΔIoD as a definition for treatment response, a significantly longer survival of responders was shown.

CONCLUSIONS: Changes in IoD after neoadjuvant treatment of GEJ cancer may be a potential surrogate for therapy response.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Graf M, Gawlitza J, Makowski M, et al. Evaluating Treatment Response in GEJ Adenocarcinoma: The Role of Pretherapeutic and Posttherapeutic Iodine Mapping. Invest Radiol. 2024. PMID: 38265075. doi:10.1097/RLI.0000000000001064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。